NCT00343499View on ClinicalTrials.gov

The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)

PHASE4TerminatedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

November 30, 2004

Study Completion Date

July 31, 2007

Conditions

Atrial Fibrillation

Interventions

DRUG

valsartan

Trial Locations (3)

84143

LDS Hospital, Salt Lake City

84403

McKay Dee Hospital, Ogden

84770

Dixie Regional Medical Center, St. George

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Intermountain Health Care, Inc.

OTHER